Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have received a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $27.33.
KALV has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on Kalvista Pharmaceuticals in a report on Friday, September 21st. They set an “overweight” rating and a $32.00 price objective on the stock. Stifel Nicolaus initiated coverage on Kalvista Pharmaceuticals in a report on Monday, October 15th. They set a “buy” rating on the stock. BidaskClub cut Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. Zacks Investment Research lowered Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Thursday, September 20th. Finally, Jefferies Financial Group initiated coverage on Kalvista Pharmaceuticals in a report on Tuesday, October 30th. They set a “buy” rating and a $30.00 price target on the stock.
In related news, Director Albert Cha purchased 1,058,824 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average price of $17.00 per share, for a total transaction of $18,000,008.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 49.10% of the company’s stock.
Shares of KALV opened at $22.40 on Wednesday. The company has a market cap of $393.57 million, a PE ratio of -14.64 and a beta of 2.94. Kalvista Pharmaceuticals has a 1 year low of $7.73 and a 1 year high of $25.57.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.14). The firm had revenue of $3.72 million for the quarter, compared to analysts’ expectations of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. As a group, equities research analysts predict that Kalvista Pharmaceuticals will post -2.07 earnings per share for the current fiscal year.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: Understanding Analyst Ratings
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.